Live Quote · NASDAQHUMAHealthcare· Biotechnology

Humacyte, Inc.

$0.71 5.56%(+$0.04)
TickerSpark Score
45/100
Weak
45
Valuation
20
Profitability
60
Growth
68
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HUMA research report →

52-Week Range7% of range
Low
$0.55
Current
$0.71
High
$2.84
Company Overviewwww.humacyte.com

About the company

Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields.

CEO
Laura E. Niklason
IPO
2020
Employees
218
HQ
Durham, NC, US

Price Chart

-69.26% · this period
$2.73$1.65$0.57Jul 02Dec 31Jul 02
Valuation
Market Cap
$119.28M
P/E
-1.21
P/S
59.17
P/B
12.08
EV/EBITDA
-1.71
Div Yield
0.00%
Profitability
Gross Margin
-748.51%
Op Margin
-5649.21%
Net Margin
-4840.82%
ROE
-2781.56%
ROIC
-117.66%
Growth & Income
Revenue
$2.04M · 0.00%
Net Income
$-40,833,000 · 72.54%
EPS
$-0.26 · 79.37%
Op Income
$-107,437,000
FCF YoY
-6.25%
Performance & Tape
52W High
$2.84
52W Low
$0.55
50D MA
$0.99
200D MA
$1.16
Beta
2.46
Avg Volume
9.99M

Get TickerSpark's AI analysis on HUMA

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 11, 26Windham-Bannister Susan Richardsother80,000
Jun 11, 26Constantino Michael T.other80,000
Jun 11, 26Wallace Max N.other80,000
Jun 11, 26Niklason Laura Eother80,000
Jun 11, 26Sebelius Kathleenother80,000
Jun 11, 26Jones Keith Anthonyother80,000
Jun 11, 26Green Charles Bruceother80,000
Jun 11, 26Seimetz Dianeother80,000
Jun 11, 26Bamforth John Philipother80,000
Jun 11, 26Brown Emery N.other80,000
Coverage · HUMA

Our HUMA coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on HUMA yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate HUMA report →
Internal Compare

Similar companies

Peers in the same neighborhood.